Covid, research and development, clinical trials: how Pfizer will invest in France

The harvest was good for the 2022 harvest of the Choose France summit, the second part of which was held in Versailles on July 11. Particularly in the area of ​​healthcare: in January, Pfizer announced its intention to invest 520 million euros over five years in France to strengthen its production and research capacities in several therapeutic areas (oncology, rare diseases, immunology, vaccines…). “Pfizer (…) is excited to invest in France, which recognizes the value of innovation and encourages growth in the healthcare sector,” said Albert Bourla, CEO of the French-based group. Hexagon over 65 years ago and today employs 1,100 people.

According to Henriette Rosenquist, president of Pfizer France, France, a country of administrative delays, regulatory heaviness and lack of funding, which is regularly pointed out by researchers and industry participants, is nevertheless a country of “attractive” investments. Problems tricolor projects of the pharmaceutical giant.

Problems. As part of your investment plan, French manufacturer Novasep has joined the global supply chain for Covid-19 treatments Paxlovid. Where is this partnership?

Henrietta Rosenquist – A significant portion of our investment is indeed directed towards fighting the Covid-19 pandemic. We have entrusted Novasep, a company we have already worked with, with the production of the active pharmaceutical ingredient (API) of our Covid-19 protease inhibitor. Thus, this manufacturer has integrated our global supply chain for this drug, which extends over three continents. This will contribute 20% to the production of 120 million boxes scheduled for this processing in 2022. After the technical handover and installation of the equipment, the Novasep plant in Murenks [Pyrénées-Atlantiques, NDLR]production began on 3 June.